Compare Amylx Pharmaceuticals Inc (AMLX) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Atlassian Corporation PLC — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Atlassian Corporation PLC trades at $89.76 (market cap $22.55B). The key difference: Atlassian Corporation PLC is far larger — about 11.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| AMLX | TEAM | |
|---|---|---|
Market Cap | $1.98B | $22.55B |
Sector | Health | Technology |
52-Week High | $18.70 | $203.00 |
52-Week Low | $7.64 | $57.15 |
Enterprise Value | $1.70B | $22.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Atlassian (TEAM) trades at $88.86, down 2.04% today, with strong technical momentum indicated by bullish moving averages. The company shows accelerating revenue growth reaching $5.22B in 2025, though it remains unprofitable with a -3.5% net margin. Recent earnings beats and cloud revenue growth of 29% in Q3 FY26 demonstrate business momentum, while analyst consensus remains strongly bullish with a $119.93 price target representing 35% upside potential.
TEAM presents a compelling growth story with improving fundamentals and strong analyst support, though profitability challenges and AI disruption risks require monitoring. The stock's current valuation at 3.77x sales appears reasonable given the 30%+ revenue growth trajectory, making it attractive for growth-oriented investors willing to accept near-term losses for long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
